<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03643328</url>
  </required_header>
  <id_info>
    <org_study_id>1608178</org_study_id>
    <secondary_id>ANSM</secondary_id>
    <nct_id>NCT03643328</nct_id>
  </id_info>
  <brief_title>Ex Vivo Evaluation of Immunity Activation Face to S. Aureus Antigens and Adjuvants of a Vaccine Candidate in Cells From Haemodialysis Patients</brief_title>
  <acronym>ANTISTAPH</acronym>
  <official_title>Ex Vivo Evaluation of Immunity Activation Face to Staphylococcus Aureus Antigens and Adjuvants of a Vaccine Candidate in Cells From Haemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      S. aureus is a leading cause of severe infections notably in haemodialysis patients. These
      patients have a high risk of S. aureus nasal carriage, with a rate of persistent carriage
      near 30%. These carriers are particularly at risk of S. aureus infections as we previously
      shown. High risk of S. aureus infections such as bacteremia occurred notably in patients with
      dialysis catheters. Decolonization of carriers may prevent such infections however this
      approach has limits. Development of an effective S. aureus vaccine is crucial. To date, past
      vaccines tested (phase III) failed to achieve their end points. Target of only one or few
      antigens, absence of cellular response induction and possibly no impact on carriage are
      probably the reasons of the failures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In an attempt to minimize failure in a clinical phase, ex vivo analysis of immune response of
      leucocytes of haemodialysis patients face to S. aureus and the impact of antigens and
      adjuvants of a candidate vaccine may help.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 14, 2017</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EX VIVO measure of innate immunity: functional capacity of neutrophils to S. aureus vaccine antigens</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Measured by blood samples at 0, 6 and 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EX VIVO measure of innate immunity: induction of oxidative burst to S. aureus vaccine antigens</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Measured by blood samples 0, 6 and 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EX VIVO measure of innate immunity : phenotype activation of different cell types from PBMCs (peripheral blood mononuclear cells) to S. aureus vaccine antigens</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Measured by blood samples 0, 6 and 12 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EX VIVO measures of innate immunity: chemokines and cytokines secretions to S. aureus vaccine antigens</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Measured by blood samples 0, 6 and 12 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EX VIVO measure of acquired immunity: measures of S. aureus antibodies titre in serum to S. aureus vaccine antigens</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Measured by blood samples 0, 6 and 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of persistant portage of S. aureus in the nose haemodialysis patients.</measure>
    <time_frame>Months 0 and 6 and 12</time_frame>
    <description>Measured by nasal swabs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of the S. aureus clonal complexes of nasal carriage strains from haemodialysis patients.</measure>
    <time_frame>Months 0 and 6 and 12</time_frame>
    <description>Measured by nasal swabs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of infection by S. aureus in new haemodialysis patients.</measure>
    <time_frame>Month 12</time_frame>
    <description>By data collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EX VIVO measure of innate immunity: functional capacity of neutrophils to S. aureus vaccine adjuvants</measure>
    <time_frame>Months 0 and 6 and 12</time_frame>
    <description>Measured by blood samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EX VIVO measure of innate immunity: induction of oxidative burst to S. aureus vaccine adjuvants</measure>
    <time_frame>Months 0 and 6 and 12</time_frame>
    <description>Measured by blood samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EX VIVO measure of innate immunity : phenotype activation of different cell types from PBMCs (peripheral blood mononuclear cells) to S. aureus vaccine adjuvants</measure>
    <time_frame>Months 0 and 6 and 12</time_frame>
    <description>Measured by blood samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EX VIVO measures of innate immunity: chemokines and cytokines secretions to S. aureus vaccine adjuvants</measure>
    <time_frame>Months 0 and 6 and 12</time_frame>
    <description>Measured by blood samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EX VIVO measure of acquired immunity: measures of S. aureus antibodies titre in serum to S. aureus vaccine adjuvants</measure>
    <time_frame>Months 0 and 6 and 12</time_frame>
    <description>Measured by blood samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigation of the presence of antigens of interest selected for the vaccine approach in strains of S. aureus in the nasal carriage</measure>
    <time_frame>Months 0 and 6 and 12</time_frame>
    <description>Measured by nasal swabs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival rate to S.aureus in the whole blood</measure>
    <time_frame>Months 0 and 6 and 12</time_frame>
    <description>Measured by blood samples. Expressed in percentage</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Staphylococcus Aureus</condition>
  <arm_group>
    <arm_group_label>new haemodialysis patients.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>There is an analyse of immune response against S. aureus from new haemodialysis patients by blood samples and nasal swabs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood samples</intervention_name>
    <description>Blood samples will be collected at inclusion, at 6 months and 12 months for hematological and immunological analyses.</description>
    <arm_group_label>new haemodialysis patients.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>nasal swabs</intervention_name>
    <description>Two nasal swabs will be collected at inclusion, at 6 months and 12 months for virology analyses.</description>
    <arm_group_label>new haemodialysis patients.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient starting haemodialysis for chronic hemodialysis.

          -  Patient starting haemodialysis on catheter

          -  Patient who signed the informed consent form

        Exclusion Criteria:

          -  Pregnant woman

          -  Patient who starts Haemodialysis for over 3 months

          -  Patient with anemia (hemoglobin &lt;7 g / dL)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth BOTELHO-NEVERS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Saint Etienne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Saint-Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 16, 2018</study_first_submitted>
  <study_first_submitted_qc>August 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Staphylococcus Aureus</keyword>
  <keyword>haemodialysis</keyword>
  <keyword>vaccine</keyword>
  <keyword>immune response</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

